Supplementary Materials

Supplementary Material for:

Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection

Matthew S. Parsons,* Sarah B. Lloyd, Wen Shi Lee, Anne B. Kristensen, Thakshila Amarasena, Rob J. Center, Brandon F. Keele, Jeffrey D. Lifson, Celia C. LaBranche, David Montefiori, Bruce D. Wines, P. Mark Hogarth, Kristine M. Swiderek, Vanessa Venturi, Miles P. Davenport, Stephen J. Kent*

*Corresponding author. Email: skent{at}unimelb.edu.au (S.J.K.); mattp{at}unimelb.edu.au (M.S.P.)

Published 9 August 2017, Sci. Transl. Med. 9, eaaf1483 (2017)
DOI: 10.1126/scitranslmed.aaf1483

This PDF file includes:

  • Fig. S1. Analysis of differences in VLs after different SHIV challenges.
  • Fig. S2. Animal infectiousness of the cell-associated SHIVSF162P3 stock challenge dose.
  • Fig. S3. PGT121 binds to macaque FcγRs and activates NK cells.
  • Fig. S4. ADCC of HIV-1–infected target cells by macaque PBMCs using PGT121.
  • Fig. S5. Anti-gp120–binding antibodies in plasma samples of SHIVSF162P3-infected macaques.
  • Fig. S6. FcγRIIIa-binding antibodies in plasma samples of SHIVSF162P3-infected macaques.
  • Fig. S7. Markers of NK cell and T cell activation in PGT121-infused animals.
  • Fig. S8. Gag-specific T cells in SHIVSF162P3-challenged macaques.
  • Fig. S9. V3 loop sequence alterations in infected animals.
  • Table S1. Characteristics of viral challenge stocks.
  • Table S2. Sensitive VL measurements in PGT121-infused cell-associated challenged macaques.
  • Table S3. Mutations within envelope.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S4 (Microsoft Excel format). Primary data.